Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study

Matthieu Schmidt, David Hajage, Guillaume Lebreton, Antoine Monsel, Guillaume Voiriot, David Levy, Elodie Baron, Alexandre Beurton, Juliette Chommeloux, Paris Meng, Safaa Nemlaghi, Pierre Bay, Pascal Leprince, Alexandre Demoule, Bertrand Guidet, Jean Michel Constantin, Muriel Farrouch, Martin Dres, Alain Combes, for the Groupe de Recherche Clinique en Réanimation et Soins intensifs du Patient en Insuffisance Respiratoire aiguë (GRC-RESPIRE) Sorbonne Université, and the Paris-Sorbonne ECMO-COVID investigators*

Summary

Background Patients with COVID-19 who develop severe acute respiratory distress syndrome (ARDS) can have symptoms that rapidly evolve to profound hypoxaemia and death. The efficacy of extracorporeal membrane oxygenation (ECMO) for patients with severe ARDS in the context of COVID-19 is unclear. We aimed to establish the clinical characteristics and outcomes of patients with respiratory failure and COVID-19 treated with ECMO.

Methods This retrospective cohort study was done in the Paris–Sorbonne University Hospital Network, comprising five intensive care units (ICUs) and included patients who received ECMO for COVID-19 associated ARDS. Patient demographics and daily pre-ECMO and on-ECMO data and outcomes were collected. Possible outcomes over time were categorised into four different states (states 1–4): on ECMO, in the ICU and weaned off ECMO, alive and out of ICU, or death. Daily probabilities of occupation in each state and of transitions between these states until day 90 post-ECMO onset were estimated with use of a multi-state Cox model stratified for each possible transition. Follow-up was right-censored on July 10, 2020.

Findings From March 8 to May 2, 2020, 492 patients with COVID-19 were treated in our ICUs. Complete day-60 follow-up was available for 83 patients (median age 49 [IQR 41–56] years and 61 [73%] men) who received ECMO. Pre-ECMO, 78 (94%) patients had been prone-positioned; their median driving pressure was 18 (IQR 16–21) cm H2O and PaO2/FiO2 was 60 (54–68) mm Hg. At 60 days post-ECMO initiation, the estimated probabilities of occupation in each state were 6% (95% CI 3–14) for state 1, 18% (11–28) for state 2, 45% (35–56) for state 3, and 31% (22–42) for state 4. 35 (42%) patients had major bleeding and four (5%) had a haemorrhagic stroke. 30 patients died.

Interpretation The estimated 60-day survival of ECMO-rescued patients with COVID-19 was similar to that of studies published in the past 2 years on ECMO for severe ARDS. If another COVID-19 outbreak occurs, ECMO should be considered for patients developing refractory respiratory failure despite optimised care.

Funding None.

Copyright © 2020 Elsevier Ltd. All rights reserved.

Introduction The 2019 outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly evolved into a worldwide pandemic, with more than 17 million cases of COVID-19 as of July 30, 2020. In France, many disease clusters were identified early in March, 2020, with Paris and its surrounding area (Greater Paris) reporting the most cases. COVID-19 can lead to acute respiratory failure requiring intensive care unit (ICU) admission and mechanical ventilation. However, its most serious forms can rapidly evolve to severe acute respiratory distress syndrome (ARDS) with profound hypoxaemia and death, despite lung-protective mechanical ventilation, including prone-positioning. 13

In 2018, the extracorporeal membrane oxygenation (ECMO) to rescue Lung Injury in severe ARDS (EOLIA; n=249) trial showed that although mortality in the ECMO group was lower at 35% compared with 46% in the control group, the difference was not significant (relative risk 0.76 [95% CI 0.55–1.04]; p=0.09). 3 A post-hoc Bayesian analysis of EOLIA data later showed a high likelihood of an ECMO survival benefit for severe ARDS, as defined by the EOLIA entry criteria. 2 Accordingly, international organisations 4 and experts in the field 3 recommended ECMO for patients who were critically ill with COVID-19 following the initial outbreak in China, further stating that it should be provided in high-volume specialised centres, and a mobile ECMO team should retrieve patients on ECMO from other centres. However, survival was very low in Chinese case series of ECMO-treated patients with COVID-19, 15 raising concerns about the usefulness of ECMO in this setting. 16
We aimed to establish the characteristics and outcomes of patients who received ECMO for laboratory-confirmed SARS-CoV-2 infection in the Paris–Sorbonne University Hospital Network ICUs, the principal hospital referral network for ICU care in Greater Paris, including one of the largest European ECMO centres (Pitié-Salpêtrière Hospital).

Methods

Study design and participants

This retrospective cohort study was done in the Paris–Sorbonne University Hospital Network ICUs (three at La Pitié–Salpêtrière Hospital, one in Saint-Antoine Hospital, and one in Tenon Hospital), which cared for patients with COVID-19 with severe ARDS. All consecutive adult patients with laboratory confirmed SARS-CoV-2 infection, documented by real-time RT-PCR on nasopharyngeal swabs, or lower respiratory tract aspirates,11 and who received venoarterial-ECMO or venovenous-ECMO for severe ARDS were included. Patients who received ECMO for isolated refractory cardiogenic shock were excluded. ECMO support was provided at Pitié-Salpêtrière and Tenon hospital ICUs, while Saint-Antoine hospital ICU cared for patients either before ECMO cannulation or after ECMO decannulation.

The Sorbonne-University Ethics Committee (CER-SU-2020-46) approved the protocol. In accordance with the ethical standards of French legislation (Committees for the Protection of Human Subjects), informed consent for demographic, physiological, and hospital-outcome data analyses was not obtained because this observational study did not modify existing diagnostic or therapeutic strategies. Only non-opposition of the patient or their legal representative for use of the data was obtained.

Procedures

In a context of ECMO resource constraints, all ECMO proposals in Greater Paris were centralised at Pitié-Salpêtrière Hospital. Once contacted, indications for ECMO were evaluated in a staff meeting, including at least two intensivists. Patients eligible for ECMO had to fulfill ARDS criteria,13 and one of the following disease severity criteria, despite ventilator optimisation (fraction of inspired oxygen [FiO2] ≥80%, tidal volume set at 6 mL/kg predicted bodyweight, and positive end-expiratory pressure [PEEP] ≥10 cm of water): (1) partial pressure of arterial oxygen (PaO2) over a FiO2 ratio of less than 50 mm Hg for more than 3 h; (2) PaO2/FiO2 less than 80 mm Hg for more than 6 h; or (3) arterial blood pH less than 7.25 with a partial pressure of arterial carbon dioxide (PaCO2) of 60 mm Hg or more for 6 h or more.11

Physicians were strongly encouraged to use neuromuscular blocking agents and prone-positioning before ECMO. ECMO contraindications were: age older than 70 years, severe comorbidities (eg, advanced cardiac, respiratory, or liver failure; metastatic cancer; or...
haematological malignancies), cardiac arrest (except when cardiopulmonary resuscitation was provided immediately and the low-flow time was <15 minutes), refractory multiorgan failure or Simplified Acute Physiology Score (SAPS) II more than 90, irreversible neurological injury, and mechanical ventilation for more than 10 days.

Once the indication was approved, the Pitié-Salpêtrière mobile ECMO retrieval team (MERT), comprising a cardiovascular surgeon and a perfusionist, was sent to the patient’s bedside for ECMO cannulation, as described previously.3,11 Our MERT was available 24 h per day, 7 days a week. Once ECMO had been implanted, the patient was transferred by a Service d’Aide Medicale d’Urgence ambulance with the MERT to one of the Paris–Sorbonne University Hospital Network ICUs.

ECMO cannulation was done percutaneously under ultrasonography guidance by a cardiovascular surgeon wearing full personal protective equipment (ie, respirator FFP2 or N95 mask, gown, goggles, and gloves). For venoarterial-ECMO, blood drainage with a large cannula (25–29 Fr) inserted into the common femoral vein, and returned through the right internal jugular vein was strongly recommended. For venoarterial-ECMO, a venous drainage cannula (23–29 Fr) was inserted into the common femoral vein, an arterial return cannula (15–19 Fr) into the common femoral artery, and an additional anterograde perfusion cannula was systematically inserted into the superficial femoral artery to prevent leg ischaemia. Pump speed was adjusted to obtain blood-oxygen saturation at more than 90%. Optimal cannula positioning was verified by ultrasonography and chest X-ray. Following early reports of severe COVID-19 associated coagulopathy13–16 and frequent thromboembolic events on ECMO, including massive pulmonary embolism,17,18 we decided to increase the targeted activated partial thromboplastin time for anticoagulation of venovenous ECMO with unfractionated heparin to 60–75 s or anti-Xa activity 0·3–0·5 IU/mL. (respective values were 40–55 s or 0·2–0·3 IU/mL in the EOLIA trial) before we treated our first patients with COVID-19 ARDS. Plasma-free haemoglobin and plasma fibrinogen concentrations were monitored daily. The haemoglobin threshold for red blood cell transfusion was 7–8 g/dL (or ≤10 g/dL when hypoxaemia persisted); platelet transfusions were discouraged except for severe thrombocytopenia (<50×10⁹ cells per L) or thrombocytopenia of more than 100×10⁹ cells per L with bleeding. To enhance protection against ventilator-induced lung injury, ultra-protective lung ventilation on ECMO was recommended,11,13 by targeting lower mechanical power delivered to the lungs and lower tidal volume, respiratory rate, and airway and driving pressures. Early prone-positioning on ECMO was encouraged in the absence of haemodynamic instability and contraindications for prone-positioning (ie, massive haemoptysis requiring an immediate surgical or interventional radiology procedure; deep venous thrombosis treated for less than 2 days, or single anterior chest tube with air leaks).13,14 Patients were assessed daily for possible ECMO weaning with use of the EOLIA clinical and physiological criteria.1,13

Information recorded before ECMO comprised age, sex, body-mass index, comorbidities, SAPS II,13 Sequential Organ-Failure Assessment score,14 Respiratory Extracorporeal Membrane Oxygenation Survival Prediction score,25 date of first symptoms, and hospital and ICU admissions. Information collected before ECMO implantation comprised previous rescue therapies, the date mechanical ventilation started, ventilator settings (mode, PEEP, FiO₂, respiratory rate, tidal volume, plateau pressure [Pplat]), arterial blood-gas parameters, and routine laboratory values. Driving pressure (ΔP) was defined as Pplat minus PEEP and mechanical power (J/min) was calculated as follows:26

\[
\text{mechanical power} = 0.098 \times \text{tidal volume} \times \text{respiratory rate} \times (\text{peak pressure} - \frac{1}{2} \times \Delta P)
\]

Ventilatory ratio was calculated as:27

\[
\frac{\text{minute ventilation} \times \text{PaCO}_2}{\text{[predicted bodyweight} \times 100 \times 37.5]}
\]

An expanded dataset including mechanical ventilation settings, arterial blood gases, adjuvant therapies on ECMO, and ECMO-related complications was noted daily from day 1–7, then every 7 days until ECMO day 60, ECMO weaning, or death, whichever occurred first. ECMO-related complications and organ dysfunction included major bleeding, blood-cell transfusions, massive haemolysis, ECMO-circuit change, severe thrombocytopenia (<50×10⁹ cells per L, occurring during the first

---

**Figure 1: Study profile**

Study profile for patients included in this study, and their outcomes at July 10, 2020. ICU=intensive care unit. ECMO=extracorporeal membrane oxygenation.
3 days of ECMO), stroke, renal replacement therapy, proven pulmonary embolism, pneumothorax, ventilator-associated pneumonia, bacteraemia, and cardiac arrest. Major bleeding was defined as requiring two or more units of packed red blood cells due to an obvious haemorrhagic event, necessitating a surgical or interventional procedure, an intracerebral haemorrhage, or a bleed causing a fatal outcome, while massive haemolysis was defined as plasma-free haemoglobin of more than 500 mg/L associated with clinical signs of haemolysis.

Outcomes
Patient outcomes comprised the following endpoints: on ECMO, in the ICU and weaned off ECMO, alive and out of ICU, or died on days 28, 40, 50, 60, 70, 80, and 90 after ECMO implantation. Time spent in each state was calculated for the whole population of 83 patients, with right-censoring of patients who did not reach the final absorbing state at later timepoints (day 70, 80, or 90). Other outcomes comprised ICU and ECMO-related complications.

Statistical analysis
Patient characteristics are expressed as n (%) for categorical variables, mean (SD) for continuous variables, or median (IQR), as appropriate.

To better describe patients’ trajectories in the ICU over time, a multi-state model was used. Briefly, this framework considers that a patient can go through different states during follow-up. Herein, the starting time was the ECMO initiation day, making on ECMO the initial state for all patients, potentially followed by two intermediate states.

| All patients (N=83) | Alive and discharged from the ICU (n=48)* | Alive and still in the ICU (n=5)† | Died (n=30) |
|---------------------|------------------------------------------|----------------------------------|-------------|
| Age, years          | 49 (41–56)                               | 45 (38–53)                       | 49 (41–58)  |
| Sex                 |                                          |                                  |             |
| Male                | 61 (73%)                                 | 34 (71%)                         | 3 (60%)     |
| Female              | 22 (27%)                                 | 14 (29%)                         | 2 (40%)     |
| Body-mass index, kg/m² | 30.4 (27.9–34.1)                 | 31.1 (27.7–34.6)                 | 28.6 (26.3–30.4) |
| Simplified Acute Physiology Score II | 45 (29–56) | 42 (28–52) | 56 (53–68) |
| RESP score          | 4 (2–5)                                  | 4 (3–5)                          | 4 (2–4)     |
| Total SOFA score l  | 12 (9–14)                                | 11 (8–12)                        | 9 (8–17)    |
| Renal component of the SOFA score of 3 or greater | 34 (12%) | 5 (10%) | 2 (40%) |
| Cardiovascular component of the SOFA score of 3 or greater | 42 (51%) | 23 (48%) | 2 (40%) |
| Haematological component of the SOFA score of 3 or greater | 2 (2%) | 0 | 2 (7%) |
| Comorbidities       |                                          |                                  |             |
| Hypertension        | 32 (39%)                                 | 17 (35%)                         | 2 (40%)     |
| Diabetes            | 26 (31%)                                 | 13 (27%)                         | 2 (40%)     |
| Ischaemic cardiomyopathy | 4 (5%)                                  | 2 (4%)                           | 0           |
| Chronic respiratory disease, COPD, or asthma | 9 (11%) | 6 (13%) | 1 (20%) |
| Active smoker       | 2 (2%)                                   | 1 (2%)                           | 0           |
| Immunocompromised§  | 3 (4%)                                   | 0                                | 0           |
| Time from first symptoms to ICU admission, days | 7 (5–10) | 7 (6–10) | 8 (5–10) |
| Time from first symptoms to intubation, days | 8 (6–11) | 9 (6–11) | 10 (5–10) |
| Time from intubation to ECMO, days | 4 (3–6) | 4 (2–5) | 7 (7–9) |
| Retrieval on ECMO by mobile ECMO retrieval team from another hospital | 61 (72%) | 34 (71%) | 3 (60%) |
| Volume-assist control ventilation | 83 (100%) | 48 (100%) | 5 (100%) |

Ventilation parameters
| FI O₂ | 100 (100–100) |
| Positive end-expiratory pressure, cm H₂O | 14 (12–14) |
| Tidal volume, ml/kg predicted bodyweight‡ | 6.0 (5.7–6.4) |
| Respiratory rate, breaths per min‡ | 29 (28–30) |
| Plateau pressure, cm H₂O | 32 (29–33) |
| Driving pressure, cm H₂O | 18 (16–21) |
| Static compliance, ml/cm H₂O | 22.1 (18.1–26.5) |
| Mechanical power, J/min|| | 24.7 (22.0–27.3) |
| Ventilatory ratio|| | 2.7 (2.3–3.2) |

(Table 1 continues on next page)
states: in the ICU and weaned off ECMO and alive and out of the ICU. Because patients could die at any time during follow-up, either in the ICU or after discharge, the died state is the only final absorbing state (the final state that a patient can enter that once entered cannot be left). In this four-state model (appendix p 9), each box represents a state and each arrow represents possible transitions from one state to another. After assessing patient status, participants who did not reach the final absorbing state were right-censored at the end of the observation period (July 10, 2020). A Cox model stratified on each possible transition was fitted to estimate transition (from one state to another) and state occupation (for each of the four states) probabilities over time; the percentages of patients occupying each possible state were represented simultaneously over time with a stacked probability plot and reported with their 95% CI on days 28, 40, 50, 60, 70, 80, and 90 post-ECMO initiation. Another figure (appendix p 15) individually displays all possible transition probabilities from one state to another over time. Mean state occupation times (ie, the expected length of stay in each possible state of the multi-state model) was also reported at the same timepoints. Finally, median on-ECMO time and length of ICU stay were established. All the analyses were computed at a two-sided α level of 5% with R software, version 4.0.0.

Role of the funding source

There was no funding source for this study. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results

Among the 492 consecutive patients (figure I) admitted to the Paris–Sorbonne University Hospital Network ICUs (Pitié–Salpêtrière [n=289]; Saint-Antoine [n=110]; and Tenon [n=93]) for COVID-19 (March 8 to May 2, 2020), 83 (Pitié–Salpêtrière [n=79]; Tenon [n=4]) received ECMO support (median age 49 [IQR 41–56] years; 61 [73%] men;
SAPS II median score 45 (29–56)). Their pre-ECMO characteristics according to their endpoint state on July 10, 2020, are reported in table 1. Briefly, pre-ECMO rescue procedures consisted of prone-positioning (n=78, 94%), continuous neuromuscular blockers (n=80, 96%), and nitric oxide (n=28, 34%). Median PEEP was 14 (IQR 12–14) cm H2O, driving pressure was 18 (16–21) cm H2O, and mechanical power was 24·7 (22·0–27·3) J/min. At cannulation, the median PaO2/FiO2 was 60 (IQR 54–68) mm Hg and PaCO2 was 57 (50–68) mm Hg. For comparison, detailed characteristics of patients with COVID-19 in our cohort and in the EOLIA trial3 group are reported in the appendix (pp 5–7).

Femoral–jugular cannulas were inserted in 79 (95%) patients, mostly with a large (29 Fr) drainage cannula, a median 4 (IQR 3–6) days after endotracheal intubation. The MERT brought 61 (73%) patients from non-ECMO centres. ECMO support successfully lowered tidal volume, respiratory rate, and plateau pressure during the 24 h following its initiation: median 2·5 (IQR 1·8–4·2) mL/kg for tidal volume, 20 (20–24 breaths per min for respiratory rate), and 27 (27–30) cm H2O for plateau pressure (table 2, appendix pp 10–12). Consequently, the mechanical power delivered to the lungs dropped to 6·1 (IQR 4·1–11·0) J/min. Arterial blood gases also normalised rapidly on ECMO (appendix pp 13–14).

On ECMO, 67 (81%) patients were prone-positioned, 80 (96%) received continuous neuromuscular blockers, five (6%) nitric oxide, and 17 (20%) high-dose corticosteroids (table 3). Median activated partial thromboplastin time ratios rose progressively over days 1–3 on ECMO: 1·3 (IQR 1·2–1·6) on day 1, 1·5 (1·3–2·0) on day 2, and 1·8 (1·4–2·6) on day 3.

On July 10, 2020, median follow-up was 104 (range 70–120) days. Complete follow-up on 60 days was available for 83 patients post-ECMO implantation, 80-day

| Type of ECMO support                  | All patients (N=83) | Alive and still in the ICU (n=48)* | Alive and discharged from the ICU (n=48)* | Died (n=30) |
|--------------------------------------|---------------------|-----------------------------------|------------------------------------------|------------|
| Femoral–jugular, venovenous          | 79 (95%)           | 47 (98%)                          | 4 (80%)                                  | 28 (93%)   |
| Femoral–femoral, venovenous          | 2 (2%)             | 0                                 | 0                                        | 2 (7%)     |
| Femoral–femoral, venoarterial        | 1 (1%)             | 0                                 | 1 (20%)                                  | 0          |
| Femoral–jugular–femoral–venoarterial-venous | 1 (1%)          | 1 (2%)                            | 0                                        | 0          |

| 29 Fr drainage cannula               | 57 (69%)           | 33 (69%)                          | 3 (60%)                                  | 21 (70%)   |
| Return cannula                       |                    |                                   |                                          |            |
| 17 Fr                                | 2 (2%)             | 1 (2%)                            | 0                                        | 1 (3%)     |
| 19 Fr                                | 21 (25%)           | 15 (31%)                          | 0                                        | 6 (20%)    |
| 21 Fr                                | 42 (51%)           | 21 (44%)                          | 4 (80%)                                  | 17 (57%)   |
| 23 Fr                                | 18 (22%)           | 11 (22%)                          | 1 (20%)                                  | 6 (20%)    |
| ECMO blood flow L/min                | 5 (4–5.5)          | 5 (4–5.5)                         | 5 (4–5.5)                               | 5 (4–5.5)  |
| Sweep gas flow, L/min                | 5 (4–6)            | 5 (4–7)                           | 5 (3–5)                                 | 5 (4–6)    |
| Membrane FmO2                         | 100% (100–100)     | 100% (100–100)                    | 100% (100–100)                          | 100% (97–100) |
| Total SOFA score day 1                | 11 (9–14)          | 10 (9–12)                         | 11 (9–17)                               | 12 (11–16) |
| Renal component of the SOFA score of 3 or greater | 20 (24%) | 7 (15%)                           | 2 (40%)                                 | 11 (37%)   |
| Cardiovascular component of the SOFA score of 3 or greater | 43 (52%) | 20 (42%)                          | 3 (60%)                                 | 20 (67%)   |
| Haematological component of the SOFA score of 3 or greater       | 4 (5%)             | 1 (2%)                            | 1 (20%)                                  | 2 (7%)     |
| Ventilation parameters               |                    |                                   |                                          |            |
| FiO2                                 | 55 (40–80)         | 60 (30–80)                        | 40 (30–70)                              | 55 (42–70) |
| Positive end-expiratory pressure, cm H2O | 12 (12–14)         | 12 (12–14)                        | 12 (12–12)                              | 12 (12–12) |
| Tidal volume, mL/kg predicted bodyweight | 2.5 (1.8–4.2)     | 2.9 (1.9–4.2)                     | 2.5 (2.3–2.8)                           | 2.2 (1.4–4.2) |
| Respiratory rate, number per min     | 20 (20–24)         | 20 (20–25)                        | 20 (20–24)                              | 20 (20–24) |
| Plateau pressure, cm H2O             | 27 (27–30)         | 27 (24–30)                        | 27 (27–27)                              | 28 (27–30) |
| Driving pressure, cm H2O             | 12 (12–14)         | 12 (12–14)                        | 12 (12–12)                              | 12 (12–12) |
| Compliance, mL/cm H2O                | 12.5 (9.0–20.0)    | 13.3 (9.6–20.1)                   | 13.9 (13.2–16.7)                        | 10.9 (7.7–18.8) |
| Mechanical power, J/min              | 6.1 (4.1–11.0)     | 6.8 (4.5–12.4)                    | 7.1 (5.6–11.1)                          | 6.1 (4.0–9.9) |
| Ventilatory ratio                    | 0.7 (0.4–1.1)      | 0.8 (0.5–1.1)                     | 0.6 (0.4–1.0)                           | 0.7 (0.4–1.1) |
| Ventilation mode                     |                    |                                   |                                          |            |
| Airway pressure release ventilation/bilevel PAPV | 70 (84%) | 42 (88%)                           | 4 (80%)                                 | 24 (80%)   |
| Volume-assist control ventilation    | 13 (16%)           | 6 (13%)                           | 1 (20%)                                 | 6 (20%)    |

(Table 2 continues on next page)
follow-up was available for 75 patients, and 90-day follow-up was available for 65 patients (appendix p 8). The estimated probabilities of being in a particular state were 6% (95% CI 3–14) for on ECMO, 18% (11–28) for in the ICU and weaned off ECMO, 45% (35–56) for alive and out of the ICU, and 31% (22–42) for deceased 60 days post-ECMO initiation (table 4). All possible transition probabilities from one state to another over time are shown in the appendix (p 15). The median durations of ECMO support were 20 (IQR 10–40) days and ICU stay were 36 (23–60) days (appendix p 8).

Major bleeding occurred in 35 (42%) patients with mouth, nose, and thorax being the main sites. Packered red blood cells were transfused into 64 (77%) patients on ECMO. With higher-level anticoagulation, haemorrhagic stroke occurring in four (5%) patients. For all ECMO-treated patients, rates of clogged circuits were 4% (n=3), intravascular haemolysis was 13% (n=11), severe thrombocytopenia during the first 3 days on ECMO was 6% (n=5), and infection at cannula insertion site was 23% (n=19; table 3). 38 (46%) patients required renal replacement therapy, ventilator associated pneumonia was diagnosed in 72 (87%), and bacteraemia was diagnosed in 40 (48%) patients. Of note, the incidence of bacteraemia was similar in patients who did or did not receive steroids, other immunomodulatory therapies such as tocilizumab, or antiviral agents. Causes of death are reported in table 3. 30 patients died.

**Discussion**

Herein, we describe a large case series of patients who received ECMO support for the most severe forms of COVID-19 ARDS. They were treated in the Paris–Sorbonne University Hospital Network ICUs, comprising five intensive care units, which are experienced in managing ARDS and ECMO. ECMO indications were based on the EOLIA trial selection criteria with an upper age limit of 70 years, and patients received highly standardised ECMO care and general ICU care. Granular information on patients' pre-ECMO characteristics, daily management, and outcomes were analysed. Contrary to preliminary results from other studies that indicated dismal outcomes with 84–100% mortality of patients who had COVID-19 and were treated with ECMO,9,29 the estimated 31% probability of day-60 mortality for our patients on ECMO was similar to those treated with ECMO in the EOLIA trial (35% at day 60)1 the large prospective LIFEGARD registry (39% at day 180).21

| Blood gases on ECMO day one | All patients (N=83) | Alive and discharged from the ICU (n=48)* | Alive and still in the ICU (n=5)† | Died (n=30) |
|-----------------------------|--------------------|------------------------------------------|----------------------------------|------------|
| pH                          | 7·40 (7·36–7·47)    | 7·40 (7·37–7·46)                         | 7·32 (7·29–7·48)                 | 7·41 (7·34–7·48) |
| PaO₂, mm Hg                 | 82 (70–100)        | 84 (71–101)                             | 79 (72–80)                       | 82 (64–98)  |
| PaCO₂, mm Hg                | 45 (40–50)         | 47 (40–50)                              | 48 (43–51)                       | 42 (38–47)  |
| SaO₂                         | 96% (93–98)        | 96% (94–98)                             | 96% (94–97)                      | 96% (92–97) |
| Arterial lactate, mmol/L     | 1·7 (1·4–2·1)      | 1·7 (1·4–2·1)                           | 2·1 (1·9–2·1)                    | 1·7 (1·4–2·1) |
| Laboratory values           |                    |                                         |                                  |            |
| Platelets, ×10⁹ cells per L  | 236 (127–299)      | 242 (187–286)                           | 375 (175–398)                    | 214 (139–305) |
| Haemoglobin, g/dL            | 9·0 (7·9–10·2)     | 9·6 (8·1–10·6)                          | 7·9 (7·1–10·5)                   | 8·5 (7·9–9·1) |
| Fibrinogen, g/LI             | 7·6 (5·6–8·1)      | 7·1 (6·0–8·4)                           | 5·2 (3·1–7·0)                    | 6·4 (5·3–7·9) |
| D–Dimers, ng/mL$             | 6890 (2350–19460)  | 8065 (2110–19730)                       | 7495 (4502–12710)                | 5620 (2970–10790) |
| aPTT ratio                   | 1·3 (1·2–1·6)      | 1·2 (1·1–1·5)                           | 1·6 (1·2–1·6)                    | 1·4 (1·3–1·8) |
| Adjuvant therapy on ECMO day 1 |                    |                                         |                                  |            |
| Any                          | 70 (84%)           | 41 (85%)                                | 2 (40%)                          | 27 (90%)   |
| Neuromuscular blockade       | 70 (84%)           | 41 (85%)                                | 2 (40%)                          | 27 (90%)   |
| Prone-positioning            | 7 (8%)             | 6 (13%)                                 | 0                                | 1 (3%)     |
| Inhaled nitric oxide         | 3 (4%)             | 1 (2%)                                  | 0                                | 2 (7%)     |
| Renal replacement therapy    | 12 (14%)           | 4 (8%)                                  | 2 (40%)                          | 6 (20%)    |
| Pneumothorax                 | 2 (2%)             | 1 (2%)                                  | 0                                | 1 (3%)     |
| Cardiac arrest               | 2 (2%)             | 0                                       | 0                                | 2 (7%)     |

Data are median (IQR) or n (%). aPTT=activated partial thromboplastin time. ECMO=extracorporeal membrane oxygenation. ICU=intensive care unit. FiO₂=fraction of inspired oxygen. PaO₂=partial pressure of arterial oxygen. PaCO₂=partial pressure of arterial CO₂. PAPV=positive airway pressure ventilation. SOFA=Sequential Organ-Function Assessment. *On July 10, 2020, of the 48 patients discharged from the ICU, 14 were still hospitalised or in a rehabilitation centre and 34 returned home. †On July 10, 2020, of the five patients still in the ICU, one remained on ECMO. 178 patients. 63 patients.

**Table 2:** Characteristics of the patients on ECMO day 1 according to their endpoint state on July 10, 2020
The pre-ECMO characteristics of our patients with COVID-19 indicated great ARDS severity before ECMO support was initiated. Their mean PaO2/FiO2 (62 [SD 18] mm Hg) was lower than for patients in the EOLIA 3 (73 [30] mm Hg) or LIFEGARD 21 (71 [34] mm Hg) trials, while pre-ECMO respiratory system compliance, driving pressure, mechanical power, and other respiratory and ventilatory parameters were similar in all three studies. Notably, our patients with COVID-19 had lower respiratory system compliance and higher driving pressure than previously reported for most patients with COVID-19 receiving mechanical ventilation,1,2 indicating extensive SARS-CoV-2-induced alveolar damage. 30 According to guidelines from 2017 and 2019 for the optimisation of care for the most severe ARDS forms,31,32 94% of our patients benefited from prone-positioning before ECMO (compared with 56% in EOLIA’ and only 26% in LIFEGARD21).

Beyond providing adequate oxygenation, high blood-flow ECMO achieves a homogeneous ultraprotective ventilation strategy, most frequently using bilevel-positive airway pressure or airway pressure-release ventilation modes, with tight control of the driving pressure.33,34 Our patients’ pre-ECMO median mechanical power reached 24·7 (IQR 22·0–27·3) J/min, although a higher mortality risk for patients with ARDS whose value exceeded 17·0 J/min has been suggested.35 Following ECMO initiation, tidal volume, driving pressure, and respiratory rate were markedly reduced in our patients, resulting in a major decrease of the median mechanical power to 6·1 (IQR 4·1–11·0) J/min, as previously reported.21 In addition, ECMO prone-positioning, used for 81% of our patients with COVID-19 (vs only 10% of patients treated with ECMO in the EOLIA trial),7 might

### Table 3: ECMO management and complications as of July 10, 2020

| All patients (N=83) | (Continued from previous column) | All patients (N=83) |
|---------------------|-----------------------------------|--------------------|
| SOFA score on ECMO day 3  | 11 (8–14) | Blood-product transfusion |
| SOFA score on ECMO day 7† | 11 (8–13) | Patients who received ≥1 red blood cell units |
| aPTT ratio ECMO day 2 | 1·5 (1·3–2·0) | Number of red blood cell units per patient |
| aPTT ratio ECMO day 3 | 1·8 (1·4–2·6) | Patients who received ≥1 platelet units |
| Adjuvant therapies on ECMO | | Patients who received ≥1 fresh-frozen plasma units |
| Received continuous neuromuscular blockers | 80 (96%) | Patients who received ≥1 fibrinogen concentrates |
| Prone-position | 67 (81%) | Stroke |
| Number of sessions on ECMO during the first 7 days | 1 (0–2) | Ischaemic |
| Nitric oxide or prostacyclin | 5 (6%) | Haemorrhagic |
| High-dose corticosteroids | 17 (20%) | Antibiotic-treated cannula infection |
| Renal replacement therapy | 38 (46%) | Pulmonary embolism |
| Received COVID-19 specific treatment | 63 (76%) | Cardiac arrest |
| Remdesivir | 8 (10%) | Tracheostomy |
| Lopinavir and ritonavir | 19 (23%) | Pneumothorax |
| Tocilizumab | 8 (10%) | Antibiotic-treated ventilator-associated pneumonia |
| Hydroxychloroquine | 16 (19%) | Number of episodes |
| High-dose corticosteroids before ECMO day 8 | 12 (14%) | 72 (87%) |
| Included in a randomised controlled trial on SARS-CoV-2 therapy | 13 (16%) | | |
| ECMO-related complications | | Cause of death¶ |
| ≥1 ECMO-circuit changes | 22 (27%) | Septic shock |
| Intravascular haemolysis | 11 (13%) | Multigland failure |
| Clogged circuit requiring change | 3 (4%) | Stroke |
| Repeat ECMO needed after decannulation | 1 (1%) | Haemorrhagic shock |
| Severe thrombocytopenia (<50 × 10⁹ cells per l) during the first 3 days | 5 (6%) | Cardiovascular shock |
| ECMO setting or insertion changes§ | 4 (5%) | ECMO-device failure |
| Heparin-induced thrombocytopenia | 2 (2%) | Other |
| Massive haemorrhage | 35 (42%) | 1 (3%) |
| Oronosal bleeding | 20 (24%) | | |
| Haemothorax | 7 (8%) | Septic shock |
| Cannula | 5 (6%) | Multiorgan failure |
| Other site | 13 (16%) | Stroke |
| | | Haemorrhagic shock |
| | | Cardiovascular shock |
| | | ECMO-device failure |
| | | Other |
| | | Septic shock |
| | | Multiorgan failure |
| | | Stroke |
| | | Haemorrhagic shock |
| | | Cardiovascular shock |
| | | ECMO-device failure |
| | | Other |
| | | Septic shock |
| | | Multiorgan failure |
| | | Stroke |
| | | Haemorrhagic shock |
| | | Cardiovascular shock |
| | | ECMO-device failure |
| | | Other |
| Data are median (IQR) or n (%) | | ECMO-related complications |
| ECMO=extracorporeal membrane oxygenation. SOFA=Sequential Organ Function Assessment. aPTT=activated partial thromboplastin time. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. *80 patients. †72 patients. ‡81 patients. §Included ECMO cannulation switches from venoarterial to venovenous (n=1); venoarterial to venous–arteriovenous (n=2). ¶30 patients. |

(Continued from previous column)
Articles

have contributed to improving their outcomes. Indeed, a 2019 retrospective series of patients with severe ARDS showed that on-ECMO prone-positioning obtained higher ECMO weaning and survival rates.22 Those thromboembolic events occurred, despite an early increase of our anticoagulation target for patients with COVID-19 receiving venovenous ECMO support, suggesting that other strategies, beyond systemic anticoagulation, are warranted to care for SARS-CoV-2 induced lung endothelial injuries. It should also be noted that haemorrhagic stroke occurred in 5% of our patients, which was more frequent than in the EOLIA trial (2%).3 The higher anticoagulation regimen, and specific SARS-CoV-2-associated vasculitis and critical illness associated microbleeds could explain this finding. However, the frequency of severe haemorrhagic events requiring transfusion in our study was similar to those of patients treated with ECMO in the EOLIA trial.1

Compared with the EOLIA trial of patients with severe ARDS (44% bacterial and 21% viral pneumonia) treated with ECMO,1 in our study of patients with COVID-19, ECMO support (median 20 [IQR 10–40] days vs 11 [7–18] days) and ICU stay (36 [23–60] days vs 23 [13–34] days) lasted longer, highlighting the great severity of SARS-CoV-2 associated pulmonary damage and organ failure. Still, the needs for circuit changes were similar to those reported in a previous venovenous ECMO series.11,12 Septic shock was the primary cause of death in 10 (33%) of 30 patients but none of them were converted to venoarterial or venoarterial-venous ECMO for cardiovascular support. Indeed, the use of these types of ECMO with other series,13,14,15,16 we also observed an unusually high on-ECMO rate of proven pulmonary embolism (19%), an event not reported for the 156 patients treated with ECMO in the EOLIA trial.3 Those thromboembolic events occurred, despite an early increase of our anticoagulation target for patients with COVID-19 receiving venovenous ECMO support, suggesting that other strategies, beyond systemic anticoagulation, are warranted to care for SARS-CoV-2 induced lung endothelial injuries. It should also be noted that haemorrhagic stroke occurred in 5% of our patients, which was more frequent than in the EOLIA trial (2%).1 The higher anticoagulation regimen, and specific SARS-CoV-2-associated vasculitis and critical illness associated microbleeds could explain this finding. However, the frequency of severe haemorrhagic events requiring transfusion in our study was similar to those of patients treated with ECMO in the EOLIA trial.1

Table 4: Outcomes
has been proposed in patients with septic shock with severe myocardial dysfunction and decreased cardiac index, which was not the case in our patients. Lastly, our antibiotic-treated ventilator-associated pneumonia rate was higher (87%) than for patients in the EOLIA trial (39%), and might reflect the longer mechanical ventilation or specific SARS-CoV-2 induced immunoparalysis. It should also be noted that few of our patients received high-dose corticosteroids.

We acknowledge several limitations to our study. First, our results have to be considered preliminary, as some patients remained in the hospital and day-90 post-ECMO outcomes were not available for all patients. However, we used a time-to-event analysis, which allowed estimation of the probabilities of remaining on ECMO, ECMO weaning, ICU discharge, or death over time, taking into account the fact that some patients’ follow-up was censored. Also, on July 10, 2020, we carefully updated follow-up of all included patients to ensure the absence of informative censoring for unbiased estimations. Second, our patients were treated in a high-volume ECMO university hospital network experienced in the care of the most severe forms of ARDS that might limit the generalisability of our observations. Third, indication for ECMO and other selection and information biases might have existed due to the limited size of our cohort of patients. Fourth, although the characteristics and outcomes of our ECMO-supported patients with COVID-19 were similar to those reported in a series of ECMO-treated patients with severe ARDS before the pandemic, we were not able to compare our patients’ outcomes to those of patients with COVID-19 who were not ECMO-supported. Fifth, only data for thrombocytopenia occurring during the first 3 days of ECMO were collected, which might have underestimated the actual rate of this complication. Lastly, we did not collect data for patients’ viral load and cannot ascertain the potential benefits of prone-positioning on ECMO, which might represent areas for future studies.

In conclusion, the survival of ECMO-rescued very sick patients with COVID-19 was similar to that reported in studies on ECMO support for severe ARDS published in the past few years. Should another COVID-19 wave occur, ECMO should be considered at an early stage for patients developing profound respiratory failure, despite optimised conventional care, including prone-positioning. Longer-term follow-up of these patients is also needed to evaluate the potential pulmonary, physical, and psychological sequelae of COVID-19.

Contributors
MS, GL, AM, GV, DL, EB, AB, JC, PM, SN, PB, PL, AD, BG, JMC, MF, MD, and AC were involved in data generation. MS, DH, and AC were involved in analysis of the data. MS, DH, and AC wrote the manuscript. All authors contributed to the revision, and read and approved the final version of the manuscript. AC takes responsibility for the integrity of the work as a whole, from inception to published article.

Declaration of interests
MS reports lecture fees from Getinge, Drager, and Xenios, outside of the submitted work. AD reports personal fees from Medtronic, Baxter, Hamilton, and Getinge; grants, personal fees, and non-financial support from Philips; personal fees and non-financial support from Fisher and Paykel; grants from French Ministry of Health; grants and personal fees from Respuiron; grants and non-financial support from Lungpacer, outside of the submitted work. JMC reports personal fees and non-financial support from Drager, GE Healthcare, Sedana Medical, Baxter, Amomed, Fisher and Paykel Healthcare, Orion, Philips Medical, and Fresenius Medical Care, and non-financial support from LPB and Bird Corporation, outside of the submitted work. MD received fees from Lungpacer (expertise, lectures). AC reports grants from Getinge, personal fees from Getinge, Baxter, and Xenios, outside of the submitted work. GV reports grants and personal fees from BioMérieux, grants from SOS Oxygène, and grants from Janssen, outside of the submitted work. All other authors declare no competing interests.

Data sharing
Individual patient data reported in this Article will be shared after de-identification (text, tables, figures, and appendices), beginning 6 months and ending 2 years after Article publication, to researchers who provide a methodologically sound proposal and after approval of an internal scientific committee. Proposals should be addressed to: alain.combes@aphp.fr. To gain access, data requestors will need to sign a data access agreement. The data from this study are not currently part of any other international collection of data.

References
1 Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020; 395: 1763–70.
2 Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020; 323: 1574–81.
3 Combos A, Hajage D, Capellier G, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med 2018; 378: 1965–75.
4 Goligher EC, Tomlinson G, Hajage D, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome and posterior probability of mortality benefit in a post hoc Bayesian analysis of a randomized clinical trial. JAMA 2018; 320: 2251–59.
5 Alhazzani W, Møller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med 2020; 48: e440–69.
6 Shekar K, Badulak J, Peek G, et al. Extracorporeal life support organization coronavirus disease 2019 interim guidelines: a consensus document from an international group of interdisciplinary extracorporeal membrane oxygenation providers. ASAIO J 2020; 66: 707–21.
7 MacLaren G, Fisher D, Brodie D. Preparing for the most critically ill patients with COVID-19: the potential role of extracorporeal membrane oxygenation. JAMA 2020; 323: 1245.
8 Ramanathan K, Antognini D, Combos A, et al. Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med 2020; 8: 538–26.
9 Henry BM, Lippi G. Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): pooled analysis of early reports. J Crit Care 2020; 58: 27–28.
10 Yang X, Cai S, Luo Y, et al. Extracorporeal membrane oxygenation for coronavirus disease 2019-induced acute respiratory distress syndrome: a multicenter descriptive study. Crit Care Med 2020; published online May 18. https://doi.org/10.1097/ CCM.0000000000004447.
11 Henry BM. COVID-19, ECMO, and lymphopenia: a word of caution. Lancet Respir Med 2020; 8: e24.
12 WHO. Clinical management of severe acute respiratory infection when COVID-19 disease is suspected. 2020. https://www.who.int/publications/i/item/clinical-management-of-covid-19 (accessed July 30, 2020).
13 Ferguson ND, Fan E, Camporota L, et al. The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med 2012; 38: 1573–82.
Survival Prediction (RESP) score. Am J Respir Crit Care Med 2019; 199: 333–41.

Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multistate models. Stat Med 2007; 26: 2389–410.

Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–62.

Gattinoni L, Chiumello D, Caironi P, et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med 2020; 46: 1099–102.

Fan E, Del Sorbo L, Goligher EC, et al. An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: mechanical ventilation in adult patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2017; 195: 1253–63.

Papazian L, Aubron C, Brochard L, et al. Formal guidelines: management of acute respiratory distress syndrome. Ann Intensive Care 2019; 9: 69.

Brodie D, Slutsky AS, Combes A. Extracorporeal life support for adults with respiratory failure and related indications: a review. JAMA 2019; 322: 557–68.

Amato MB, Meade MO, Slutsky AS, et al. Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med 2015; 372: 747–55.

Serpa Neto A, Deliberato RO, Johnson AEW, et al. Mechanical power of ventilation is associated with mortality in critically ill patients: an analysis of patients in two observational cohorts. Intensive Care Med 2018; 44: 1914–22.

Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endotheliitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020; 383: 120–28.

Klok FA, Kruip MJHA, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res 2020; 191: 148–50.

Poussy J, Goutay J, Caplan M, et al. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation 2020; 142: 184–86.

Bréchot N, Luyt CE, Schmidt M, et al. Venoarterial extracorporeal membrane oxygenation support for refractory cardiovascular dysfunction during severe bacterial septic shock. Crit Care Med 2013; 41: 1616–26.